Participated · Series B · Oct 2025

CraftBank is a Tokyo-based construction DX company that develops and operates Craft Bank Office, a SaaS platform that streamlines business management for construction firms. The software is complemented by an online order-placement marketplace that links general contractors with subcontractors and craftsmen, improving both efficiency and sales opportunities. To foster offline relationships, the company hosts Shokunin Sakaba, a weekly networking event now held in 34 prefectures. Originating from an interior construction business and led by CEO Han Eiji, CraftBank aims to create a system that allows world-class craftsmen and construction companies to earn greater profits. In October 2025 the company raised ¥3.8 billion in Series B funding, bringing its total capital raised to that figure. The new funds will be directed toward strengthening nationwide support systems, expanding AI-driven product development, and deepening regional collaboration with local construction companies.

Participated · Series E · Mar 2024

Rakuten Medical, founded in 2010 and headquartered in San Diego, develops photoimmunotherapy using its Alluminox® platform, which combines targeted drug conjugates and light-delivery devices. Its lead asset, ASP-1929 (an antibody-dye conjugate using cetuximab and IRDye® 700DX), is approved in Japan for unresectable locally advanced or recurrent head and neck cancer and is being evaluated outside Japan. ASP-1929 is currently in a global Phase 3 trial in combination with pembrolizumab as a first-line treatment for recurrent head and neck cancer, with the company aiming to generate pivotal data to support a planned BLA submission to the U.S. FDA in 2028. Rakuten Medical is enrolling patients across the U.S., Japan, Taiwan, and Ukraine, with Poland sites expected to activate soon. The company is expanding its pipeline through internal programs and investigator-initiated trials, and plans a Phase 1 study of RM-0256 in Japan expected to begin in Q2 2026 with Japanese government grant support. Rakuten Medical operates offices in the United States, Japan, Taiwan, Switzerland and India and continues to grow its commercial presence in Japan to support global expansion.

Participated · Equity · Oct 2023

Spectee is a Tokyo-based resilience technology company that develops Spectee SCR, a cloud platform enabling manufacturers to map multi-tier supply chains, monitor real-time risk signals, and collaborate with suppliers to counter disasters, geopolitical shocks, and other threats. The software aggregates live data to give instant visualization of crises, allowing users to identify hidden vulnerabilities across global operations. In addition to risk detection, the platform provides collaboration tools so suppliers and OEMs can coordinate responses within the same interface. The firm positions itself as a critical partner for manufacturers seeking to strengthen business continuity and ESG compliance. To date Spectee has raised ¥3.25 billion in cumulative funding, fueling product enhancements and market expansion. The latest capital will be used to scale the business and further develop Spectee SCR’s feature set. Spectee is led by CEO Kenjiro Murakami.

Participated · Series B · May 2023

Gitai develops space robotics hardware and systems for on-orbit services and lunar infrastructure construction. The company is building robotic satellites for on-orbit services, lunar robotic rovers for infrastructure construction, and inchworm-type robotic arms usable in both areas, with all technologies developed in-house. Gitai aims to reduce the cost of space operations by 100 times. Led by CEO Sho Nakanose, the company relocated its headquarters from Japan to the United States in late 2023 and now operates from Torrence, CA. Since the move, Gitai has expanded its U.S. space and defense market presence and production capabilities, achieving selection for NASA SBIR, orders from DARPA, a technology demonstration outside the ISS, AS9100 and NIST SP800-171 certifications, and expanded headquarters and production facilities. Financially, Gitai's Series B extension has totaled US$60.5M following an additional US$15.5M raised in the latest tranche. Gitai develops space-ready robotic systems — notably a two-meter “inchworm” robotic arm and a lunar rover — intended to perform excavation, inspection, assembly and welding for space infrastructure. The company tests technologies in simulated environments such as a Mojave Desert lunar surface and a mock regolith chamber, and has completed a technology demonstration aboard the ISS Nanoracks Bishop Airlock. Gitai is preparing to deploy a 1.5-meter autonomous arm called “S2” outside the Airlock next year, pending NASA safety review, and is discussing a 2026 lunar demonstration to build communication antennas and solar panels. The seven-year-old company has offices in California and Japan and will use new funding to increase its California headcount and deepen relationships with NASA, U.S. commercial space firms and the Department of Defense. Financially, Gitai closed an additional $15 million in funding following a $30 million Series B extension announced a little over three months earlier; the recent financing also included a loan from MUFG Bank. Participating investors named in the most recent round are Green Co-Invest Investment Limited Partnership, Pacific Bays Capital’s Pacific Bays Fund 1 & 1A Investment Limited Partnerships, and MSIVC 2021V Venture Capital Investment Limited Partnership. Gitai develops autonomous robots for in-space applications, notably a robotic arm and a robotic rover designed for assembly, inspection and routine maintenance. The company aims to replace costly and dangerous human labor in space to enable construction of lunar and Martian infrastructure such as solar panels, communication antennas, fuel generators and habitation modules. Gitai demonstrated its robotic arm on the International Space Station in 2021 and is preparing a more difficult external ISS demo next year, while targeting a lunar rover mission as early as 2026. It is investing in U.S. operations—relocating leadership and engineers to Los Angeles, pausing hiring in Japan, and planning to add 20 U.S. employees by year-end and 40–50 by the end of next year. The company is building testing facilities including a mock lunar environment and a vacuum chamber to raise its technological readiness level. Financially, Gitai closed a $30 million (¥4 billion) Series B extension from a syndicate of Japanese funds and venture firms and will use the proceeds to expand U.S. manufacturing, testing capacity and workforce. GITAI develops general-purpose robots intended to perform labor inside and outside space stations, conduct orbital servicing (docking, lifespan extension, debris removal), and support lunar exploration and base development. The company positions its robots as Robots-as-a-Service to reduce astronaut risk and dramatically lower transportation and training costs for space labor. A technical demonstration of GITAI robots on the International Space Station was scheduled for summer 2021. GITAI operates as GITAI Inc. and has a U.S. branch, GITAI USA; Nakano Sho is listed as CEO. Epson has agreed to partner operationally by investigating GITAI's core technologies, dispatching engineers to the company, and promoting open innovation through personnel exchanges. No operating or financial metrics are disclosed in the article. GITAI, founded in 2016 and based in Tokyo, builds robots to service satellites, replace batteries or hardware, and support astronauts in construction and maintenance of space outposts. Its G1 is a two-armed, 120-kg general-purpose helper with autonomous abilities and remote operation via the H1 telepresence control system. The company emphasizes motor-drive control and tight integration of hardware and software — including motion planning, electronics and sensors — to perform in zero gravity. GITAI has worked with major clients including JAXA and commercial space businesses, and staged experiments in a mockup of the ISS Kibo module. It was selected to deploy S1, a 1-meter robotic arm, to the station in 2021 to be fitted onto Nanoracks’ Bishop airlock. The company plans to use robots first outside the ISS, then on the lunar surface (potentially as rovers or construction machines) to extend human capabilities in space.

Participated · Series C · Aug 2022

Ubie, founded in 2017 and based in New York, offers the Ubie AI Symptom Checker, a medically vetted platform that guides users to appropriate care pathways using predictive models. The company supports over 1,800 provider organizations and leverages disease-prediction AI to help patients navigate healthcare systems. As of June 2025 Ubie has secured over $125 million in cumulative funding. The reported capital will be used to support U.S. expansion, develop generative AI for patient education, and continue refining provider-focused solutions in partnership with the Mayo Clinic. Investors named in the report include Google, JAPAN POST CAPITAL, NTT DOCOMO, SEVEN-ELEVEN JAPAN, Japan Finance Corporation and The Shoko Chukin Bank. Ubie is a healthtech company founded in May 2017 that builds AI-powered products to guide people to appropriate medical care. Its consumer offerings include the symptom search engine Ubie (Japanese and US versions) and Ubie Disease Q&A, together reaching about 10 million monthly users. For healthcare providers it offers Ubie AI Medical Navi, a digital intake and diagnosis-support tool adopted by more than 1,700 medical institutions since its 2018 launch. The company also operates matching businesses that connect consumers and medical providers and has collaborated with pharmaceutical firms, engaging with over two-thirds of global mega‑pharma since its pharma business launch in late 2021. Ubie established a U.S. office in 2022 as part of its international expansion. It plans to use recent funding to grow its pharma-facing business, enhance consumer service features, develop new businesses, and invest in system development and marketing for the Ubie platform. Ubie provides an AI-powered symptom checker app for consumers and a B2B hospital product called Ubie for Hospital (AI Monshin) that automates preliminary patient interviews. AI Monshin selects and asks around 20 questions from 3,500 question types using data extracted from about 50,000 medical research papers. More than 1,100 medical institutions in Japan use AI Monshin, and the consumer app has over 7 million monthly active users. The company employs approximately 200 people. Ubie launched its symptom checker in the U.S. earlier this year, opened a U.S. subsidiary in October, and entered Singapore in August as initial steps toward global expansion. It plans to scale its healthcare platform and ramp up U.S. penetration, while pursuing partnerships with pharmaceutical companies (many based on the U.S. East Coast). Ubie offers an AI-powered patient questionnaire that guides patients from symptoms to appropriate medical care and improves operational efficiency in the medical field. The company is led by CEO Yoshinori Abe. It is building a medical data platform to connect patients, medical institutions, and pharmaceutical companies. Ubie says the platform will help ensure patients visit the right medical institution at the right time and help physicians access relevant, up-to-date knowledge. The company also aims to help pharmaceutical companies provide patients with appropriate information and scientific findings related to their conditions. Ubie intends to use its recent funding to support business growth in Japan and the U.S.